134 related articles for article (PubMed ID: 9593123)
21. Role of Asp104 in the SHV beta-lactamase.
Bethel CR; Hujer AM; Hujer KM; Thomson JM; Ruszczycky MW; Anderson VE; Pusztai-Carey M; Taracila M; Helfand MS; Bonomo RA
Antimicrob Agents Chemother; 2006 Dec; 50(12):4124-31. PubMed ID: 16982784
[TBL] [Abstract][Full Text] [Related]
22. Dissemination of transferable CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli in Korea.
Jeong SH; Bae IK; Kwon SB; Lee JH; Song JS; Jung HI; Sung KH; Jang SJ; Lee SH
J Appl Microbiol; 2005; 98(4):921-7. PubMed ID: 15752339
[TBL] [Abstract][Full Text] [Related]
23. Cefotaxime and ceftazidime-resistant Escherichia coli isolate producing TEM-15 beta-lactamase from a Tunisian hospital.
Chouchani C; Ben-Achour N; M'charek A; Belhadj O
C R Biol; 2007 Aug; 330(8):565-70. PubMed ID: 17637436
[TBL] [Abstract][Full Text] [Related]
24. OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene.
Poirel L; Girlich D; Naas T; Nordmann P
Antimicrob Agents Chemother; 2001 Feb; 45(2):447-53. PubMed ID: 11158739
[TBL] [Abstract][Full Text] [Related]
25. Novel extended-spectrum TEM-type beta-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalothin.
Chanal-Claris C; Sirot D; Bret L; Chatron P; Labia R; Sirot J
Antimicrob Agents Chemother; 1997 Mar; 41(3):715-6. PubMed ID: 9056022
[TBL] [Abstract][Full Text] [Related]
26. High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognition.
De Wals PY; Doucet N; Pelletier JN
Protein Sci; 2009 Jan; 18(1):147-60. PubMed ID: 19177359
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of the genes encoding extended-spectrum beta-lactamases, in Escherichia coli resistant to beta-lactam and non-beta-lactam antibiotics.
Matar GM; Al Khodor S; El-Zaatari M; Uwaydah M
Ann Trop Med Parasitol; 2005 Jun; 99(4):413-7. PubMed ID: 15949189
[TBL] [Abstract][Full Text] [Related]
28. Evolution of TEM-type extended-spectrum β-lactamases in Escherichia coli by cephalosporins.
Clasen J; Birkegård AC; Græsbøll K; Folkesson A
J Glob Antimicrob Resist; 2019 Dec; 19():32-39. PubMed ID: 31048029
[TBL] [Abstract][Full Text] [Related]
29. [Predominant β-lactamase genotypes of Escherichia coli isolates and induction and inhibition mechanisms of β-lactamase gene expression].
Tan P; Wang Z; Sun A; Yan J; Zhao J
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 May; 36(5):484-90. PubMed ID: 26080639
[TBL] [Abstract][Full Text] [Related]
30. Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance.
Schmidtke AJ; Hanson ND
Antimicrob Agents Chemother; 2006 Jun; 50(6):2030-7. PubMed ID: 16723562
[TBL] [Abstract][Full Text] [Related]
31. Amino acid substitutions causing inhibitor resistance in TEM beta-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum beta-lactamases.
Randegger CC; Hächler H
J Antimicrob Chemother; 2001 May; 47(5):547-54. PubMed ID: 11328764
[TBL] [Abstract][Full Text] [Related]
32. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
[TBL] [Abstract][Full Text] [Related]
33. Substitution of serine for arginine in position 162 of TEM-type beta-lactamases extends the substrate profile of mutant enzymes, TEM-7 and TEM-101, to ceftazidime and aztreonam.
Collatz E; Tran Van Nhieu G; Billot-Klein D; Williamson R; Gutmann L
Gene; 1989 May; 78(2):349-54. PubMed ID: 2506109
[TBL] [Abstract][Full Text] [Related]
34. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
[TBL] [Abstract][Full Text] [Related]
35. TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
Robin F; Delmas J; Brebion A; Dubois D; Constantin JM; Bonnet R
Antimicrob Agents Chemother; 2007 Nov; 51(11):4181-3. PubMed ID: 17709463
[TBL] [Abstract][Full Text] [Related]
36. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes.
Siu LK; Lu PL; Hsueh PR; Lin FM; Chang SC; Luh KT; Ho M; Lee CY
J Clin Microbiol; 1999 Dec; 37(12):4020-7. PubMed ID: 10565924
[TBL] [Abstract][Full Text] [Related]
37. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli.
Bauernfeind A; Grimm H; Schweighart S
Infection; 1990; 18(5):294-8. PubMed ID: 2276823
[TBL] [Abstract][Full Text] [Related]
38. Contribution of natural amino acid substitutions in SHV extended-spectrum beta-lactamases to resistance against various beta-lactams.
Randegger CC; Keller A; Irla M; Wada A; Hächler H
Antimicrob Agents Chemother; 2000 Oct; 44(10):2759-63. PubMed ID: 10991857
[TBL] [Abstract][Full Text] [Related]
39. Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants.
Schroeder WA; Locke TR; Jensen SE
Antimicrob Agents Chemother; 2002 Nov; 46(11):3568-73. PubMed ID: 12384366
[TBL] [Abstract][Full Text] [Related]
40. A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli.
Mirelis B; Rivera A; Miró E; Mesa RJ; Navarro F; Coll P
Enferm Infecc Microbiol Clin; 2006; 24(6):370-2. PubMed ID: 16792938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
